Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence

IF 45.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2024-02-12 DOI:10.1038/s41575-024-00904-5

Jordan Hindson

引用次数: 0

查看原文本刊更多论文

将辛替利马单抗作为辅助疗法，用于高复发风险的切除型 HCC 患者

在中国进行的一项多中心随机 II 期试验评估了 PD1 抑制剂辛替利单抗作为辅助疗法用于已接受根治性切除术的微血管侵犯肝细胞癌（HCC）患者的情况。这些患者的复发风险很高。患者（n = 198）被随机分配到辛替利单抗（静脉注射，每3周一次，共8个周期）或积极监测。无复发生存期（RFS）达到了主要终点：在中位随访23.3个月后，辛替利单抗组和对照组的中位RFS分别为27.7个月和15.5个月（P = 0.002）。在接受辛替利单抗治疗的患者中，12.4%出现了3级或4级治疗相关不良事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.

文献相关原料

公司名称	产品信息	采购帮参考价格